Aventis/Novartis Merger Would Infuse New Blood Into Novartis' Cardiology R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
The combined cardiovascular portfolio would be a strategic fit since Aventis has focused more on acute indications, while Novartis has targeted chronic conditions. Oncology would be largest therapeutic area.